Compare Halliburton Company (HAL) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halliburton Company vs Regeneron Pharmaceuticals Inc — how do they compare? Halliburton Company trades at $32.55 (market cap $27.14B), while Regeneron Pharmaceuticals Inc trades at $746.54 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.8× Halliburton Company's market cap, and Halliburton Company pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Halliburton Company for 89 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| HAL | REGN | |
|---|---|---|
Market Cap | $27.14B | $76.14B |
Volume | 11,258,156 | 500,239 |
Sector | Energy | Health |
52-Week High | $42.98 | $852.03 |
52-Week Low | $21.82 | $557.73 |
Typical Hold Time | 89 Days | 107 Days |
Enterprise Value | $33.29B | $70.85B |
Dividend Yield | 2.09% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Halliburton (HAL) trades at $32.57, up 2.58% on the day, with a bearish technical signal but strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Recent news highlights expansion in Venezuela and a major contract win in Cyprus, signaling growth initiatives. Financials show solid profitability with a 7.16% net margin and manageable debt levels, though 2025 revenue dipped slightly year-over-year.
The outlook is cautiously optimistic, driven by international expansion and analyst bullishness, with a consensus price target of $43.11 implying significant upside. Key risks include oil price volatility and execution challenges in new markets, but the company's fundamentals and institutional sentiment support a favorable long-term view for investors seeking energy sector exposure.
Regeneron Pharmaceuticals (REGN) trades at $739.57, down 0.34% with a bearish technical signal. The company maintains strong fundamentals with a 27.86% net income margin and consistent earnings beats. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront payments and milestone potential. Cash flow improved significantly in 2025 with $635 million net cash flow versus negative flows in prior years.
The stock presents a compelling investment case with strong profitability, positive analyst sentiment (69% buy ratings), and a $849.84 consensus price target offering 15% upside. Key risks include competitive pressures in ophthalmology drugs and reliance on key partnerships. The expanded Sanofi collaboration and promising clinical pipeline provide catalysts for growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
